发明公开
EP1351692A1 ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR
审中-公开
口服制剂含回肠胆汁酸转运和一抑制剂的一个HMG Co-A还原酶抑制剂
- 专利标题： ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR
- 专利标题（中）： 口服制剂含回肠胆汁酸转运和一抑制剂的一个HMG Co-A还原酶抑制剂
-
申请号： EP01974487.9申请日： 2001-10-12
-
公开(公告)号： EP1351692A1公开(公告)日： 2003-10-15
- 发明人: STARKE, Ingemar , ABRAHAMSSON, Bertil , UNGELL, Anna-Lena , LINDQVIST, Ann-Margret
- 申请人： AstraZeneca AB
- 申请人地址： 151 85 Södertälje SE
- 专利权人： AstraZeneca AB
- 当前专利权人： AstraZeneca AB
- 当前专利权人地址： 151 85 Södertälje SE
- 代理机构： Padget, Lucy Clare
- 优先权： SE0003766 20001018
- 国际公布： WO02032428 20020425
- 主分类号： A61K31/505
- IPC分类号： A61K31/505 ; A61P3/06 ; A61K31/40
摘要：
An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor in the ileum and the HBG Co A reducetase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.
信息查询
